Collegium Pharma (COLL) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Collegium Reports Net Income of $8.1 Million in the Second Quarter of 2020
August 5, 2020 4:02 PM EDT Non-GAAP Net Income of $33.2 Million in the Second Quarter of 2020
Generated $43.9 Million in Cash from Operating Activities in the Second Quarter of 2020
Xtampza ® ER Net Revenue Increased 29% over the Prior Year Period
Conference Call Scheduled for Today at 4:30 p.m. ET
STOUGHTON, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Â Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today reported... More
